| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 490.22% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 11/08/2023 | 304.72% | Wedbush | → $24 | Reiterates | Outperform → Outperform |
| 08/10/2023 | 304.72% | Wedbush | → $24 | Reiterates | Outperform → Outperform |
| 08/09/2023 | 490.22% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 07/18/2023 | 304.72% | Wedbush | → $24 | Reiterates | Outperform → Outperform |
| 07/18/2023 | 490.22% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 05/10/2023 | 304.72% | Wedbush | → $24 | Reiterates | → Outperform |
| 05/10/2023 | 490.22% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 04/06/2023 | 304.72% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
| 03/13/2023 | 490.22% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 11/14/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/06/2021 | 490.22% | B of A Securities | → $35 | Initiates Coverage On | → Buy |
| 07/06/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/06/2021 | 490.22% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
What is the target price for Janux Therapeutics (JANX)?
The latest price target for Janux Therapeutics (NASDAQ: JANX) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $35.00 expecting JANX to rise to within 12 months (a possible 490.22% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Janux Therapeutics (JANX)?
The latest analyst rating for Janux Therapeutics (NASDAQ: JANX) was provided by HC Wainwright & Co., and Janux Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Janux Therapeutics (JANX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Janux Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Janux Therapeutics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Janux Therapeutics (JANX) correct?
While ratings are subjective and will change, the latest Janux Therapeutics (JANX) rating was a reiterated with a price target of $0.00 to $35.00. The current price Janux Therapeutics (JANX) is trading at is $5.93, which is within the analyst's predicted range.